Peter Mesenbrink

Dr. Peter Mesenbrink


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Clinical Therapeutics
Verified
Journal Article
Open access
EMElias Laurin Meyer
Elias Laurin Meyer
PMPeter Mesenbrink
Peter Mesenbrink
CDCornelia Dunger-Baldauf
Cornelia Dunger-Baldauf
HFHans-Jürgen Fülle
Hans-Jürgen Fülle
EGEkkehard Glimm
Ekkehard Glimm
FKFranz König
Franz König
Recent years have seen a change in the way that clinical trials are being conducted. There has been a rise of designs more flexible than traditional adaptive and group sequential trials which allow the investigation of multiple substudies with possibly different objectives, interventions, and subgroups conducted within an overall trial structure, summarized by the term master protocol. This review aims to identify existing master protocol studies and summarize their characteristics. The review also identifies articles relevant to the design of master protocol trials, such as proposed trial designs and related methods. We conducted a comprehensive systematic search to review current literature on master protocol trials from a design and analysis perspective, focusing on platform trials and considering basket and umbrella trials. Articles were included regardless of statistical complexity and classified as reviews related to planned or conducted trials, trial designs, or statistical methods. The results of the literature search are reported, and some features of the identified articles are summarized. Most of the trials using master protocols were designed as single-arm (n = 29/50), Phase II trials (n = 32/50) in oncology (n = 42/50) using a binary endpoint (n = 26/50) and frequentist decision rules (n = 37/50). We observed an exponential increase in publications in this domain during the last few years in both planned and conducted trials, as well as relevant methods, which we assume has not yet reached its peak. Although many operational and statistical challenges associated with such trials remain, the general consensus seems to be that master protocols provide potentially enormous advantages in efficiency and flexibility of clinical drug development. Master protocol trials and especially platform trials have the potential to revolutionize clinical drug development if the methodologic and operational challenges can be overcome.

29 February 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MMMatthew McTeer
Matthew McTeer
DADouglas Applegate
Douglas Applegate
PMPeter Mesenbrink
Peter Mesenbrink
VRVlad Ratziu
Vlad Ratziu
JSJörn M. Schattenberg
Jörn M. Schattenberg
OIon behalf of the LITMUS Consortium investigators
on behalf of the LITMUS Consortium investigators
Aims: Metabolic dysfunction Associated Steatotic Liver Disease (MASLD) outcomes such as MASH (metabolic dysfunction associated steatohepatitis), fibrosis and cirrhosis are ordinarily determined by resource-intensive and invasive biopsies. We aim to show that routine clinical tests offer sufficient information to predict these endpoints. Methods: Using the LITMUS Metacohort derived from the European NAFLD Registry, the largest MASLD dataset in Europe, we create three combinations of features which vary in degree of procurement including a 19-variable feature set that are attained through a routine clinical appointment or blood test. This data was used to train predictive models using supervised machine learning (ML) algorithm XGBoost, alongside missing imputation technique MICE and class balancing algorithm SMOTE. Shapley Additive exPlanations (SHAP) were added to determine relative importance for each clinical variable. Results: Analysing nine biopsy-derived MASLD outcomes of cohort size ranging between 5385 and 6673 subjects, we were able to predict individuals at training set AUCs ranging from 0.719-0.994, including classifying individuals who are At-Risk MASH at an AUC = 0.899. Using two further feature combinations of 26-variables and 35-variables, which included composite scores known to be good indicators for MASLD endpoints and advanced specialist tests, we found predictive performance did not sufficiently improve. We are also able to present local and global explanations for each ML model, offering clinicians interpretability without the expense of worsening predictive performance. Conclusions: This study developed a series of ML models of accuracy ranging from 71.9—99.4% using only easily extractable and readily available information in predicting MASLD outcomes which are usually determined through highly invasive means.

8 October 2022 in Journal of Hepatology
Verified
Journal Article
Open access
JPJuan M. Pericàs
Juan M. Pericàs
Frank TackeFrank Tacke
Frank Tacke
QAQuentin M. Anstee
Quentin M. Anstee
NPNicholas A. Di Prospero
Nicholas A. Di Prospero
MKMette Skalshøj Kjær
Mette Skalshøj Kjær
VRVlad Ratziu
Vlad Ratziu
Non-alcoholic fatty liver disease is a condition that affects 25% of the population. Non-alcoholic steatohepatitis (NASH) is a progressive form of the disease that can lead to severe complications such as cirrhosis and hepatocellular carcinoma. Despite its high prevalence, no drugs are currently approved for the treatment of NASH. The drug development pipeline in NASH is very active, yet most assets do not progress to phase III trials and those that do reach phase III often fail to achieve the endpoints necessary for approval by regulatory agencies. Amongst other reasons, the methodological and operational features of traditional clinical trials in NASH might impede optimal drug development. In this regard, platform trials might be an attractive complement or alternative to conventional clinical trials. Platform trials use a master protocol which enables evaluation of multiple investigational medicinal products concurrently or sequentially with a single, shared control arm. Through Bayesian interim analyses, these trials allow for early exit of drugs from the trial based on success or futility, while providing participants better chances of receiving active compounds through adaptive randomisation. Overall, platform trials represent an alternative for patients, pharmaceutical companies, and clinicians in the quest to accelerate the approval of pharmacologic treatments for NASH.

31 January 2022 in Pharmaceutical Statistics
Verified
Journal Article
Open access
PDF file
EMElias Laurin Meyer
Elias Laurin Meyer
PMPeter Mesenbrink
Peter Mesenbrink
CDCornelia Dunger‐Baldauf
Cornelia Dunger‐Baldauf
EGEkkehard Glimm
Ekkehard Glimm
YLYuhan Li
Yuhan Li
ECEU‐PEARL (EU Patient‐cEntric clinicAl tRial pLatforms) Consortium
EU‐PEARL (EU Patient‐cEntric clinicAl tRial pLatforms) Consortium
Platform trials have become increasingly popular for drug development programs, attracting interest from statisticians, clinicians and regulatory agencies. Many statistical questions related to designing platform trials—such as the impact of decision rules, sharing of information across cohorts, and allocation ratios on operating characteristics and error rates—remain unanswered. In many platform trials, the definition of error rates is not straightforward as classical error rate concepts are not applicable. For an open‐entry, exploratory platform trial design comparing combination therapies to the respective monotherapies and standard‐of‐care, we define a set of error rates and operating characteristics and then use these to compare a set of design parameters under a range of simulation assumptions. When setting up the simulations, we aimed for realistic trial trajectories, such that for example, a priori we do not know the exact number of treatments that will be included over time in a specific simulation run as this follows a stochastic mechanism. Our results indicate that the method of data sharing, exact specification of decision rules and a priori assumptions regarding the treatment efficacy all strongly contribute to the operating characteristics of the platform trial. Furthermore, different operating characteristics might be of importance to different stakeholders. Together with the potential flexibility and complexity of a platform trial, which also impact the achieved operating characteristics via, for example, the degree of efficiency of data sharing this implies that utmost care needs to be given to evaluation of different assumptions and design parameters at the design stage.

26 March 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
QNQuynh Lan Nguyen
Quynh Lan Nguyen
KHKatharina Hees
Katharina Hees
SPSabina Hernandez Penna
Sabina Hernandez Penna
FKFranz König
Franz König
MPMartin Posch
Martin Posch
BHBenjamin Hofner
Benjamin Hofner
Although platform trials have many benefits, the complexity of these designs may result not only in increased methodological but also regulatory and ethical challenges. These aspects were addressed as part of the IMI project EU Patient‐Centric Clinical Trial Platforms (EU‐PEARL). We reviewed the available guidelines on platform trials in the European Union and the United States. This is supported and complemented by feedback received from regulatory interactions with the European Medicines Agency and the US Food and Drug Administration. Throughout the project we collected the needs of all relevant stakeholders including ethics committees, regulators, and health technology assessment bodies through active dialog and dedicated stakeholder workshops. Furthermore, we focused on methodological aspects and where applicable identified the corresponding guidance. Learnings from the guideline review, regulatory interactions, and workshops are provided. Based on these, a master protocol template was developed. Issues that still need harmonization or clarification in guidelines or where further methodological research is needed are also presented. These include questions around clinical trial submissions in Europe, the need for multiplicity control across the whole master protocol, the use of non‐concurrent controls, and the impact of different randomization schemes. Master protocols are an efficient and patient‐centered clinical trial design that can expedite drug development. However, they can also introduce additional operational and regulatory complexities. It is important to understand the different requirements of stakeholders upfront and address them in the trial. While relevant guidance is increasing, early dialog with relevant stakeholders can help to further support such designs.

1 August 2020 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
RDR. Dunn
R. Dunn
JGJ. Greenhouse
J. Greenhouse
DJD. James
D. James
DOD. Ohlssen
D. Ohlssen
PMPeter Mesenbrink
Peter Mesenbrink